AR117139A1 - Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) - Google Patents
Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)Info
- Publication number
- AR117139A1 AR117139A1 ARP190103417A ARP190103417A AR117139A1 AR 117139 A1 AR117139 A1 AR 117139A1 AR P190103417 A ARP190103417 A AR P190103417A AR P190103417 A ARP190103417 A AR P190103417A AR 117139 A1 AR117139 A1 AR 117139A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- alkoxy
- membered
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente proporciona compuestos heterocíclicos que tienen la fórmula general (1) en donde A, B, L, X, R¹, R², R³ y R⁴ son como se describen en el presente documento, composiciones que incluyen los compuestos, procesos para fabricar los compuestos y métodos de uso de los compuestos. Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: (i) X es C-R⁵; L es un enlace covalente, -(CH₂)ₙ-N(alquilo C₁₋₆)-, -(CH₂)ₙ-NH-, -N(alquil C₁₋₆)-(CH₂)ₚ-, -NH-(CH₂)ₚ-, -(CH₂)ₙ-O-, -O-(CH₂)ₚ-, -SO₂-N(alquilo C₁₋₆)-, -SO₂-NH-, -N(alquil C₁₋₆)-SO₂-, -NH-SO₂-, carbonilo, -(CH₂)ₙ-, -CHR⁶-, -CF₂-(CH₂)ₙ-, -(CH₂)ₚ-CF₂-, -(CH₂)ₙ-S-, -S-(CH₂)ₚ-, -SO₂-, -C(O)-NH-, -C(O)-N(alquilo C₁₋₆)-, -NH-C(O)- o -N(alquil C₁₋₆)-C(O)-; y A es: (i) arilo C₆₋₁₄ sustituido con R⁷, R⁸ y R⁹; o (ii) heteroarilo de 5 - 14 miembros sustituido con R¹⁰, R¹¹ y R¹²; o (ii) X es N; L es un enlace covalente, -(CH₂)ₙ-, -CHR⁶ -, -SO₂-, carbonilo, -N(alquil C₁₋₆)-(CH₂)ₚ-, -NH-(CH₂)ₚ-, -O-(CH₂)ₚ-, -CF₂-CH₂-, -N(alquil C₁₋₆)-SO₂-, -NH-SO₂-, -NH-C(O)- o -N(alquil C₁₋₆)-C(O)-; y A es: (i) arilo C₆₋₁₄ sustituido con R⁷, R⁸ y R⁹; o (ii) heteroarilo de 5 - 14 miembros sustituido con R¹⁰, R¹¹ y R¹²; o (iii) X es N; L es alcoxi C₁₋₆-carbonilo, ariloxicarbonilo C₆₋₁₄ o heteroariloxicarbonilo de 5 - 14 miembros; y A está ausente; B es un espirociclo bicíclico; R¹, R², R³, R⁴ y R⁵ son independientemente hidrógeno, halógeno, hidroxi, alquilo C₁₋₆ o halo-alquilo C₁₋₆; R⁶ es arilo C₆₋₁₄ o heteroarilo de 5 - 14 miembros; R⁷, R⁸, R⁹, R¹⁰, R¹¹ y R¹² son en cada aparición independientemente hidrógeno, hidroxi, alquilo C₁₋₆, halo-alquilo C₁₋₆, halógeno, alcoxi C₁₋₆, halo-alcoxi C₁₋₆, SF₅, alquil C₁₋₆sulfonilo, ciano o un grupo de fórmula (2); C es heteroarilo de 5 - 14 miembros, heterociclilo de 3 - 14 miembros o cicloalquilo C₃₋₁₀; RC¹, RC² y RC³ son cada uno independientemente hidrógeno, alquilo C₁₋₆, halo-alquilo C₁₋₆, oxo, halógeno, hidroxi, alcoxi C₁₋₆ o halo-alcoxi C₁₋₆; cada aparición de n es independientemente 0, 1, 2 ó 3; cada aparición de p es independientemente 1, 2 ó 3; y q es 0, 1 ó 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18207725 | 2018-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR117139A1 true AR117139A1 (es) | 2021-07-14 |
Family
ID=64453331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190103417A AR117139A1 (es) | 2018-11-22 | 2019-11-21 | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) |
Country Status (30)
Country | Link |
---|---|
US (1) | US20210387999A1 (es) |
EP (1) | EP3883936B1 (es) |
JP (1) | JP7444882B2 (es) |
KR (1) | KR20210094540A (es) |
CN (1) | CN113166170A (es) |
AR (1) | AR117139A1 (es) |
AU (1) | AU2019383500A1 (es) |
BR (1) | BR112021009348A2 (es) |
CA (1) | CA3119506A1 (es) |
CL (1) | CL2021001330A1 (es) |
CO (1) | CO2021007056A2 (es) |
CR (1) | CR20210247A (es) |
DK (1) | DK3883936T3 (es) |
ES (1) | ES2955037T3 (es) |
FI (1) | FI3883936T3 (es) |
HR (1) | HRP20231083T1 (es) |
HU (1) | HUE062913T2 (es) |
IL (1) | IL283333B1 (es) |
LT (1) | LT3883936T (es) |
MA (1) | MA55131B1 (es) |
MX (1) | MX2021005714A (es) |
PE (1) | PE20211870A1 (es) |
PH (1) | PH12021551167A1 (es) |
PL (1) | PL3883936T3 (es) |
PT (1) | PT3883936T (es) |
RS (1) | RS64579B1 (es) |
SG (1) | SG11202104206SA (es) |
SI (1) | SI3883936T1 (es) |
TW (1) | TWI825227B (es) |
WO (1) | WO2020104494A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
AU2019322538B2 (en) | 2018-08-13 | 2021-09-30 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
BR112022002375A2 (pt) | 2019-09-12 | 2022-07-19 | Hoffmann La Roche | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl |
JP2023542908A (ja) * | 2020-09-18 | 2023-10-12 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | カルボニル複素環系化合物及びその使用 |
WO2023130043A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment of anxiety |
WO2023130050A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain |
WO2023144160A1 (en) * | 2022-01-25 | 2023-08-03 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
WO2024033277A1 (en) | 2022-08-08 | 2024-02-15 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
WO2024033479A1 (en) * | 2022-08-11 | 2024-02-15 | Remynd N.V. | (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders |
WO2024061853A1 (en) * | 2022-09-20 | 2024-03-28 | F. Hoffmann-La Roche Ag | Fluorescent probes for magl |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
JP5658756B2 (ja) | 2009-09-10 | 2015-01-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Jakの阻害剤 |
WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
JP5990297B2 (ja) | 2015-03-03 | 2016-09-14 | タイヨーエレック株式会社 | 遊技機 |
WO2016158956A1 (ja) * | 2015-03-30 | 2016-10-06 | 武田薬品工業株式会社 | 複素環化合物 |
EA033680B1 (ru) | 2015-05-21 | 2019-11-15 | Glaxosmithkline Ip Dev Ltd | Производные бензоимидазола в качестве ингибиторов pad4 |
BR112018000041A2 (pt) | 2015-07-31 | 2018-09-04 | Pfizer Inc. | Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl |
WO2017087858A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
-
2019
- 2019-11-20 KR KR1020217015287A patent/KR20210094540A/ko unknown
- 2019-11-20 EP EP19809026.8A patent/EP3883936B1/en active Active
- 2019-11-20 SG SG11202104206SA patent/SG11202104206SA/en unknown
- 2019-11-20 CR CR20210247A patent/CR20210247A/es unknown
- 2019-11-20 CN CN201980077284.5A patent/CN113166170A/zh active Pending
- 2019-11-20 RS RS20230788A patent/RS64579B1/sr unknown
- 2019-11-20 HU HUE19809026A patent/HUE062913T2/hu unknown
- 2019-11-20 PT PT198090268T patent/PT3883936T/pt unknown
- 2019-11-20 HR HRP20231083TT patent/HRP20231083T1/hr unknown
- 2019-11-20 PL PL19809026.8T patent/PL3883936T3/pl unknown
- 2019-11-20 LT LTEPPCT/EP2019/081870T patent/LT3883936T/lt unknown
- 2019-11-20 WO PCT/EP2019/081870 patent/WO2020104494A1/en active Application Filing
- 2019-11-20 ES ES19809026T patent/ES2955037T3/es active Active
- 2019-11-20 JP JP2021528972A patent/JP7444882B2/ja active Active
- 2019-11-20 CA CA3119506A patent/CA3119506A1/en active Pending
- 2019-11-20 PE PE2021000714A patent/PE20211870A1/es unknown
- 2019-11-20 MX MX2021005714A patent/MX2021005714A/es unknown
- 2019-11-20 IL IL283333A patent/IL283333B1/en unknown
- 2019-11-20 MA MA55131A patent/MA55131B1/fr unknown
- 2019-11-20 SI SI201930619T patent/SI3883936T1/sl unknown
- 2019-11-20 AU AU2019383500A patent/AU2019383500A1/en active Pending
- 2019-11-20 BR BR112021009348-6A patent/BR112021009348A2/pt unknown
- 2019-11-20 DK DK19809026.8T patent/DK3883936T3/da active
- 2019-11-20 FI FIEP19809026.8T patent/FI3883936T3/fi active
- 2019-11-21 TW TW108142267A patent/TWI825227B/zh active
- 2019-11-21 AR ARP190103417A patent/AR117139A1/es unknown
-
2021
- 2021-05-20 CL CL2021001330A patent/CL2021001330A1/es unknown
- 2021-05-20 US US17/325,934 patent/US20210387999A1/en active Pending
- 2021-05-21 PH PH12021551167A patent/PH12021551167A1/en unknown
- 2021-05-28 CO CONC2021/0007056A patent/CO2021007056A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
AR110922A1 (es) | Compuestos inhibidores del vih | |
AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
AR106945A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
AR110405A1 (es) | Compuestos | |
AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
AR113299A1 (es) | Compuestos de isoindolina | |
AR113929A1 (es) | Compuestos heterocíclicos | |
AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR119943A1 (es) | Compuestos heterocíclicos | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
AR088810A1 (es) | Moduladores del receptor mas acoplado a la proteina g utiles en el tratamiento de trastornos cardiovasculares y composiciones farmaceuticas que los contienen | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
AR108610A1 (es) | Derivados de imidazolona inhibidores de la elastasa de neutrófilos humana |